Servier Finalizes $2.5 Billion Deal to Acquire Day One, Targeting Rare Cancers

SURESNES, France and BRISBANE, Calif. – March 06, 2026 – In a strategic move set to reshape the rare oncology landscape, French pharmaceutical group Servier today announced a definitive agreement to acquire Day One Biopharmaceuticals for approximately $2.5 billion. The all-cash transaction, priced at $21.50 per share, represents a significant investment by Servier to bolster its pipeline and establish itself as a leader in treating rare and pediatric cancers.

The acquisition, which sent Day One's stock (NASDAQ: DAWN) soaring by nearly 65%, is a cornerstone of Servier's ambitious "2030 Ambition" strategy to become a focused and innovative player in oncology. By integrating Day One, Servier gains control of Ojemda (tovorafenib), a recently approved and highly promising therapy for pediatric low-grade glioma (pLGG), the most common form of childhood brain cancer.

"This acquisition of Day One Biopharmaceuticals marks another decisive step in strengthening Servier's position in rare oncology," said Olivier Laureau, President of Servier, in a statement. "It reflects our long-term commitment to investing in science that can make a meaningful difference for patients. This announcement is fully aligned with our 2030 ambition, and we believe that combining our expertise will accelerate innovation for people living with a rare cancer."

A Strategic Play for a Specialized Market

For Servier, a group governed by a foundation rather than public shareholders, the acquisition is a calculated step toward its goal of generating 4 billion euros in oncology revenue by 2030. The company has been methodically building its cancer franchise, focusing on areas with high unmet medical needs. This deal is not just an expansion but a strategic deepening of its capabilities, particularly in neuro-oncology.

Servier already markets Voranigo, a drug approved in 2024 for glioma in patients with specific IDH1 or IDH2 mutations. The addition of Day One’s Ojemda, which targets a different genetic driver (BRAF alterations), creates a powerful and complementary portfolio in the fight against brain tumors. This synergy positions Servier to address a wider spectrum of glioma patients, from adults to very young children, and solidifies its presence in a challenging therapeutic area.

The deal is expected to close in the second quarter of 2026, pending customary closing conditions, including shareholder approval and U.S. antitrust clearance. Day One's Board of Directors has unanimously recommended that its shareholders tender their shares in favor of the acquisition.

The Crown Jewel: Ojemda's Impact on Pediatric Cancer

The centerpiece of the acquisition is unquestionably Ojemda (tovorafenib). This type 2 RAF inhibitor received accelerated FDA approval in April 2024, marking a watershed moment for pediatric oncology. It is the first and only approved monotherapy for children aged six months and older with relapsed or refractory pLGG that harbors a BRAF fusion, rearrangement, or V600 mutation.

Pediatric low-grade gliomas, while often slow-growing, can be devastating. When tumors are located in inoperable areas of the brain or recur after initial treatment, children face a chronic disease requiring repeated, often harsh, therapies that can impair their development and quality of life. Until Ojemda, there were no systemic therapies specifically approved for the large subset of these tumors driven by BRAF fusions.

Ojemda's clinical data from the pivotal FIREFLY-1 trial, published in Nature Medicine, demonstrated its profound impact. The study showed an overall response rate of 64% and a clinical benefit rate of 91% in its initial patient cohort. Follow-up data presented in late 2025 further underscored its durability, with a median duration of response of 19.4 months and many young patients remaining off therapy for extended periods. Its once-weekly oral dosing also offers a significant quality-of-life advantage over more intensive daily regimens.

"Joining Servier represents a unique opportunity to extend the reach of our science and our lead program in pediatric low–grade glioma," stated Jeremy Bender, Ph.D., chief executive officer of Day One. He emphasized that Servier’s commitment to the rare disease community aligns with the "patient–first mindset" that has defined Day One since its founding.

With a pivotal Phase 3 trial (FIREFLY-2) underway to evaluate Ojemda as a front-line treatment, Servier is now poised to potentially establish a new standard of care for newly diagnosed patients, a market with significant unmet need. Ojemda's sales, which reached $155.4 million in 2025, are projected to grow to between $225 million and $250 million in 2026, providing an immediate revenue stream to fuel further development.

A Bellwether Deal in a Rebounding M&A Market

The $2.5 billion price tag, representing a 68% premium over Day One's closing price on March 5, reflects the high value placed on de-risked, innovative assets in the current biopharmaceutical landscape. The deal is seen as a bellwether for a rebounding M&A market in 2026, where large pharmaceutical companies are flush with cash and facing looming patent expirations, creating an urgent need to replenish their pipelines.

After a more muted 2025, industry analysts have predicted a surge in acquisitions, with a particular focus on companies with differentiated science and clear paths to market. The Servier-Day One transaction perfectly fits this mold. Servier is not just buying a single product but a specialized platform, including Day One's other pipeline assets like Emi-Le, an antibody-drug conjugate (ADC) in Phase 1 trials for solid tumors.

Financial markets reacted swiftly and positively to the news. Following the announcement, analysts at several firms adjusted their ratings on Day One to "Hold," with price targets aligning to the $21.50 offer, signaling that the valuation is considered fair and the deal likely to proceed. The acquisition underscores a broader industry trend: a strategic pivot towards rare diseases and precision oncology, where scientific innovation can lead to premium pricing and address critical patient needs in smaller, more defined populations.